Review
Published on 28 Sep 2018
Quality, Non-clinical and Clinical Considerations for Biosimilar Monoclonal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM Regulatory Guidelines
in Drugs Outcomes Research and Policies
Frontiers in Pharmacology
doi 10.3389/fphar.2018.01079
- 19,245 views
- 29 citations
